This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
neoadjuvant
A collection of 47 issues
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases
Skip to content
The CRC Digest
◆ TRIAL DATA
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine
A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — April 06, 2026
Today's colorectal cancer research highlights
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Skip to content
The CRC Digest
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Exceptional case of synchronous colon cancers with different MMR status provides direct in vivo evidence of ICI responsiveness differences. (Japanese Journal of Clinical Oncology)
This content is informational only and does